Mother microbiological presence (mutans streptococci colonisation level, CFU/mL) · For interventions, pregnant women and mothers of infants in the first year of life; for outcomes, children up to 6 years of age
Consumption of xylitol chewing gum by women (mothers) led to higher mother microbiological presence (mutans streptococci colonisation… compared with consumption of CHX/xylitol gum by women, or CHX varnish applied to…; GRADE not reported.
1 finding from 1 review
defs index score · For interventions, pregnant women and mothers of infants in the first year of life; for outcomes, children up to 6 years of age
It is very uncertain whether consumption of xylitol chewing gum by women (mothers) changes defs index score (categories) compared with consumption of CHX/xylitol gum by women, or CHX varnish applied to… (very low certainty).
2 findings from 1 review
Thorild 2003 defs score categories (very low-certainty): 1-3 defs RR 0.48 (95% CI 0.15 to 1.54); 3-4 defs RR 0.85 (95% CI 0.18 to 3.98); >=5 defs RR 0.28 (95% CI 0.01 to 6.78); 96 participants.
1 study · 96 participants
Very low
MD -0.28 [-0.83, 0.27]
1 study · 96 participants
Very low
Patient discomfort · People with temporomandibular disorders (TMD)
The review found no eligible studies for this question.
1 finding from 1 review
Discomfort/pain · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Dental caries · For interventions, pregnant women and mothers of infants in the first year of life; for outcomes, children up to 6 years of age
The review found no eligible studies for this question.
2 findings from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Gabapentin changes risk for at least one adverse event per patient compared with pregabalin (very low certainty).
1 finding from 1 review
Risk for at least one adverse drug reaction (ADR) per participant · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Kappa‐opioid agonists may leads to higher risk for at least one adverse drug reaction (ADR) per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Cromolyn sodium changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Topical capsaicin may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · health problem or population
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
Summary of findings table ‐ Naltrexone may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in burn‐related pruritus (VAS) ( · people with postburn pruritus
Enalapril ointment showed no clear difference in change in burn‐related pruritus (Scoring table for itching) ( compared with placebo (moderate certainty).
1 finding from 1 review
Pain VAS for pain ( · people with postburn pruritus
Massage therapy showed no clear difference in pain VAS for pain ( compared with standard care (low certainty).
1 finding from 1 review
Surgery for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes surgery for recurrent or persistent disease compared with preoperative pharmacological therapy and surgery (very low certainty).
1 finding from 1 review
Non‐surgical therapy for recurrent or persistent diseaseRadiation therapy and/or pharmacologic therapy for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes non‐surgical therapy for recurrent or persistent diseaseRadiation… compared with preoperative pharmacological therapy and surgery (very low certainty).
1 finding from 1 review